Skip to main content

Advertisement

Table 3 The multiplicity of P. falciparu m infection and mean titer of anti-MSP1 antibodies, in subjects with antibodies that are either highly competitive (H) or poorly competitive (L) with the specific monoclonal antibodies.

From: Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum Merozoite Surface Protein 1 types in individuals in Nigeria with sub-microscopic infection

aMonoclonal antibody Number of subjects cInfection dAntibodies to rMSP1
  Total n = 147 bInfected M S MOI Prevalence P Mean log titre P
12.8          
Poorly competitive (L) 100 99 50 49 1.73 78% 0.0006 2.3 0.0001
Highly competitive (H) 46 43 22 21 1.65 100%   3.2  
12.10          
Poorly competitive (L) 90 87 38* 49 0.86 77% 0.002 2.4 0.0001
Highly competitive (H) 57 56 35 21 0.98 96%   2.9  
12.8 and 12.10          
Poorly competitive (L) 75 74 33 ** 41 1.62 73% 0.0007 2.3 0.0001
Highly competitive (H) 32 31 18 13 1.77 100%   3.2  
  1. aMonoclonal antibody. mAb12.10 and mAb 12.8: L and H refer to the number of individuals with antibodies that are either poorly competitive or highly competitive with the monoclonal antibodies, respectively.
  2. bInfected: number of subjects positive by PCR.
  3. cInfection: M refers to individuals with two or more parasite clones, S refers to individuals with only one parasite type detected. MOI is the mean multiplicity of infection based on MSP1 block 2 alleles.
  4. dAntibodies to rMSP1: Prevalence is the number of subjects with antibodies against recombinant MSP1 as a percentage of the total.